Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

122.92 +1.99 (+1.65%)
Streaming Delayed Price Updated: 1:46 PM EDT, May 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 634,278
Open 122.41
Bid (Size) 122.80 (2)
Ask (Size) 123.05 (1)
Prev. Close 120.93
Today's Range 120.91 - 123.55
52wk Range 110.03 - 238.00
Shares Outstanding 145,800,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Biogen Beats Q1 Earnings Expectations As Two Newcomer Drug Sales Spike, Avoids Tariff Impact
Biogen beat Q1 earnings and revenue estimates, raised rare disease drug sales, and cut its 2025 EPS guidance due to a $165 million collaboration payment. 
Via Benzinga
Biogen (NASDAQ:BIIB) Beats Q1 Sales Targets
Biotech company Biogen (NASDAQ:BIIB) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 6.1% year on year to $2.43 billion. Its non-GAAP profit of $3.02 per share was... 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence

Performance

YTD
-18.1%
-18.1%
1 Month
-6.9%
-6.9%
3 Month
-15.9%
-15.9%
6 Month
-29.4%
-29.4%
1 Year
-43.1%
-43.1%

More News

Read More
Biogen Easily Tops Earnings Forecasts As Leqembi, Skyclarys Sales Soar
Via Investor's Business Daily
Topics Earnings
Exposures Financial
Earnings Scheduled For May 1, 2025
Via Benzinga
Biogen Earnings: What To Look For From BIIB
Via StockStory
Topics Artificial Intelligence World Trade
Exposures Artificial Intelligence Tariff
14 Analysts Have This To Say About Biogen
Via Benzinga
How Is The Market Feeling About Biogen?
Via Benzinga
1 Safe-and-Steady Stock with Promising Prospects and 2 to Ignore
Via StockStory
Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction
Via Benzinga
Topics Government
Exposures Political
Europe Approves Eisai-Biogen's Alzheimer's Drug 'Under Strict Conditions' After Initial Negative Opinion
Via Benzinga
Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union
From Biogen Inc.
Via GlobeNewswire
Trump Wants RFK Jr. To 'Go Wild' On Health Care. What This Means For Biotech Stocks.
Via Investor's Business Daily
Topics Government
Exposures Political Product Safety
Spotting Winners: United Therapeutics (NASDAQ:UTHR) And Therapeutics Stocks In Q4
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
What 14 Analyst Ratings Have To Say About Biogen
Via Benzinga
Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire
European Drug Regulator Gives Thumbs Down To Eli Lilly's Alzheimer's Drug, Analyst Says It Is Incremental Win For Biogen
Via Benzinga
Beyond GLP-1 Drugs: This Opportunity at Eli Lilly Could Surprise Everyone in 2025
Via The Motley Fool
Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square
From Biogen Inc.
Via GlobeNewswire
Q4 Rundown: Moderna (NASDAQ:MRNA) Vs Other Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
Via Benzinga
Q4 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Novartis New Data From Single-Dose Gene Therapy Shows Meaningful Efficacy, Safety In Patients With Spinal Muscular Atrophy
Via Benzinga
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
From Biogen Inc.
Via GlobeNewswire
Indexes Swimming In Red Ink On Recession Fears
Via Talk Markets
Topics Economy Stocks / Equities
Exposures Economy

Frequently Asked Questions

Is Biogen Idec publicly traded?
Yes, Biogen Idec is publicly traded.
What exchange does Biogen Idec trade on?
Biogen Idec trades on the Nasdaq Stock Market
What is the ticker symbol for Biogen Idec?
The ticker symbol for Biogen Idec is BIIB on the Nasdaq Stock Market
What is the current price of Biogen Idec?
The current price of Biogen Idec is 122.92
When was Biogen Idec last traded?
The last trade of Biogen Idec was at 05/02/25 01:46 PM ET
What is the market capitalization of Biogen Idec?
The market capitalization of Biogen Idec is 17.92B
How many shares of Biogen Idec are outstanding?
Biogen Idec has 18B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.